World

Did Trump reveal that the US has begun ground attacks in Venezuela?

Dec 30, 2025

Washington [US], December 30: US President Donald Trump announced on December 29 that the US had "attacked" an area in Venezuela believed to be where drugs were being loaded onto trains, according to Reuters.
"There was a big explosion in the harbor area where the drugs were being loaded onto the ships. We attacked all the ships, and now we've attacked the area... that's the distribution area. That's the distribution area, and that area no longer exists," Trump told reporters at his Mar-a-Lago resort in Florida.
Trump's statement marks the first time Washington has conducted ground operations in Venezuela since the campaign to pressure the government of President Nicolas Maduro began, according to Reuters. The Trump administration accuses President Maduro of running a drug cartel, but Maduro has denied the accusation.
When asked whether the Central Intelligence Agency (CIA) carried out the aforementioned attack, Trump said, "I don't want to say that." Earlier, Trump had stated that he had authorized the CIA to conduct covert operations in Venezuela.
The CIA, the White House, and the Pentagon have not publicly commented on Trump's recent statements and declined to answer Reuters' questions. The Venezuelan government has not commented on the incident described by Trump, and there has been no independent report from Venezuela on the matter.
Later, the US military announced on social media platform X that they had carried out another deadly attack on a ship in the Eastern Pacific, killing two people and bringing the total death toll in Washington's anti-drug campaign at sea to at least 107, according to AFP.
Source: Thanh Nien Newspaper

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026